230 related articles for article (PubMed ID: 1632467)
1. Overexpression of p53 protein in basal cell carcinomas of human skin.
Shea CR; McNutt NS; Volkenandt M; Lugo J; Prioleau PG; Albino AP
Am J Pathol; 1992 Jul; 141(1):25-9. PubMed ID: 1632467
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic analysis of the p53 gene in non-melanoma skin cancer and correlation with apoptosis and cell proliferation.
Stratigos AJ; Kapranos N; Petrakou E; Anastasiadou A; Pagouni A; Christofidou E; Petridis A; Papadopoulos O; Kokka E; Antoniou C; Georgala S; Katsambas AD
J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):180-6. PubMed ID: 15752287
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53 protein in actinic keratosis, adjacent, normal-appearing, and non-sun-exposed human skin.
Einspahr J; Alberts DS; Aickin M; Welch K; Bozzo P; Grogan T; Nelson M
Cancer Epidemiol Biomarkers Prev; 1997 Aug; 6(8):583-7. PubMed ID: 9264270
[TBL] [Abstract][Full Text] [Related]
4. Mutation spectra of epidermal p53 clones adjacent to basal cell carcinoma and squamous cell carcinoma.
Bäckvall H; Strömberg S; Gustafsson A; Asplund A; Sivertsson A; Lundeberg J; Ponten F
Exp Dermatol; 2004 Oct; 13(10):643-50. PubMed ID: 15447725
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma.
Ansarin H; Daliri M; Soltani-Arabshahi R
Eur J Dermatol; 2006; 16(5):543-7. PubMed ID: 17101476
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression.
Maurer TA; Christian KV; Kerschmann RL; Berzin B; Palefsky JM; Payne D; Tyring SK; Berger TG
Arch Dermatol; 1997 May; 133(5):577-83. PubMed ID: 9158410
[TBL] [Abstract][Full Text] [Related]
7. Human patched (PTCH) mRNA is overexpressed consistently in tumor cells of both familial and sporadic basal cell carcinoma.
Undén AB; Zaphiropoulos PG; Bruce K; Toftgård R; Ståhle-Bäckdahl M
Cancer Res; 1997 Jun; 57(12):2336-40. PubMed ID: 9192803
[TBL] [Abstract][Full Text] [Related]
8. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas.
Bolshakov S; Walker CM; Strom SS; Selvan MS; Clayman GL; El-Naggar A; Lippman SM; Kripke ML; Ananthaswamy HN
Clin Cancer Res; 2003 Jan; 9(1):228-34. PubMed ID: 12538474
[TBL] [Abstract][Full Text] [Related]
10. Carcinogen-specific mutation pattern in the p53 tumour suppressor gene in UV radiation-induced basal cell carcinoma.
Weihrauch M; Bader M; Lehnert G; Wittekind C; Tannapfel A; Wrbitzky R
Int Arch Occup Environ Health; 2002 Apr; 75(4):272-6. PubMed ID: 11981662
[TBL] [Abstract][Full Text] [Related]
11. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan.
Hsu CH; Yang SA; Wang JY; Yu HS; Lin SR
Br J Cancer; 1999 Jun; 80(7):1080-6. PubMed ID: 10362120
[TBL] [Abstract][Full Text] [Related]
12. Analyses of the tumour suppressor ING1 expression and gene mutation in human basal cell carcinoma.
Chen B; Campos EI; Crawford R; Martinka M; Li G
Int J Oncol; 2003 Apr; 22(4):927-31. PubMed ID: 12632089
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation state of tumor-suppressor gene p53 product overexpressed in skin tumors.
Matsumoto M; Furihata M; Kurabayashi A; Ohtsuki Y
Oncol Rep; 2004 Nov; 12(5):1039-43. PubMed ID: 15492790
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 and 17p allelic loss in colorectal carcinoma.
Cunningham J; Lust JA; Schaid DJ; Bren GD; Carpenter HA; Rizza E; Kovach JS; Thibodeau SN
Cancer Res; 1992 Apr; 52(7):1974-80. PubMed ID: 1551126
[TBL] [Abstract][Full Text] [Related]
15. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
Bazan V; Migliavacca M; Tubiolo C; Macaluso M; Zanna I; Corsale S; Amato A; Calò V; Dardanoni G; Morello V; La Farina M; Albanese I; Tomasino RM; Gebbia N; Russo A
J Cell Physiol; 2002 May; 191(2):237-46. PubMed ID: 12064467
[TBL] [Abstract][Full Text] [Related]
16. bcl-2 vs p53 protein expression and apoptotic rate in human nonmelanoma skin cancers.
Wikonkal NM; Berg RJ; van Haselen CW; Horkay I; Remenyik E; Begany A; Hunyadi J; van Vloten WA; de Gruijl FR
Arch Dermatol; 1997 May; 133(5):599-602. PubMed ID: 9158413
[TBL] [Abstract][Full Text] [Related]
17. [Immunomorphological features of cutaneous basal-cell carcinoma].
Chuprov IN
Vopr Onkol; 2008; 54(6):715-9. PubMed ID: 19241845
[TBL] [Abstract][Full Text] [Related]
18. Infrequent p53 mutations in arsenic-related skin lesions.
Castrén K; Ranki A; Welsh JA; Vähäkangas KH
Oncol Res; 1998; 10(9):475-82. PubMed ID: 10223623
[TBL] [Abstract][Full Text] [Related]
19. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of p53 protein is common in premalignant head and neck lesions.
Pavelic ZP; Li YQ; Stambrook PJ; McDonald JS; Munck-Wikland E; Pavelic K; Dacic S; Danilovic Z; Pavelic L; Mugge RE
Anticancer Res; 1994; 14(5B):2259-66. PubMed ID: 7840533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
